je.st

Home › gilead

Tag: gilead

Biz Break: Gilead hepatitis C drugs rack up more huge sales, cash headed to investors

2015-02-04 02:13:49| Biotech - Topix.net

Today: Gilead Sciences completes a transformational financial year with another huge quarter, thanks to sales of Foster City company's breakthrough hepatitis C medications, and will push that cash back to investors as discounts begin to take effect. Also: Twitter jumps amid changes.

Tags: to sales break cash

Gilead Announces Executive Promotions

2015-01-29 08:15:08| Biotech - Topix.net

Gilead Sciences, Inc. today announced the promotion of Andrew Cheng, MD, PhD to Executive Vice President, HIV Therapeutics and Development Operations, and Taiyin Yang, PhD, to the role of Executive Vice President, Pharmaceutical Development and Manufacturing. Dr. Cheng and Dr. Yang will both join Gilead's senior leadership committee.

Tags: executive promotions announces gilead

Gilead Expands Hepatitis C Generic Licensing Agreements to Include...

2015-01-26 12:49:40| Biotech - Topix.net

FOSTER CITY, Calif.-- -- Gilead Sciences, Inc. today announced that the company has expanded its hepatitis C generic licensing agreements to include the investigational NS5A inhibitor GS-5816, which is being evaluated in Phase 3 clinical studies as part of a single tablet regimen that combines the compound and sofosbuvir for the treatment of all six genotypes of hepatitis C. The expanded agreements will allow Gilead's India-based partners to manufacture GS-5816 and the single tablet regimen of sofosbuvir/GS-5816, once approved, for distribution in 91 developing countries, which together account for 54 percent of the total worldwide population of individuals infected with the hepatitis C virus .

Tags: include generic licensing agreements

Investment Firm Names Gilead Sciences, Inc.'s CEO Of 2014

2015-01-23 15:38:04| Auto Parts - Topix.net

Morningstar Names John Martin Of Gilead Sciences As Its 2014 CEO Of The Year CHICAGO, Jan. 21, 2015 /PRNewswire/ -- Morningstar, Inc. MORN, +2.87% a leading provider of independent investment research, today named John Martin of Gilead Sciences the recipient of its 2014 CEO of the Year award. Each year Morningstar recognizes a chief executive who exhibits commendable corporate stewardship, demonstrates independent thinking, creates lasting value for shareholders, and has put his or her stamp on an industry.

Tags: names firm investment sciences